Rhoda M. Alani, MD is the Herbert Mescon Professor and Chair of Dermatology at Boston University School of Medicine and Boston Medical Center. She received her MD degree with Honors and Distinction in Research from the University of Michigan and completed her internship in internal medicine at Yale-New Haven Hospital and a residency in dermatology at Harvard Medical School. From 1999-2009 Dr. Alani was the Director of the Laboratory of Cutaneous Oncology and Director of the Melanoma and Pigmented Lesion Clinics in Dermatology at Johns Hopkins. Dr. Alani’s research focus is in understanding the molecular basis of melanoma development and progression with the aim of translating her laboratory findings to better prevention, detection, diagnosis, and treatment of melanoma. Dr. Alani is a member of Phi Beta Kappa and Alpha Omega Alpha Honor Societies, the American Academy of Dermatology, the Society for Investigative Dermatology, the American Association for Cancer Research and was elected to the American Society for Clinical Investigation in 2005. She is the author of numerous scientific publications and is the owner of several US patents related to melanoma biomarkers, novel melanoma therapies, and imaging systems for improved melanoma detection
- Herbert Mescon Chair , Dermatology, Boston University School of Medicine
- Professor, Pathology & Laboratory Medicine, Boston University School of Medicine
- Member, BU-BMC Cancer Center, Boston University
- Member, Genome Science Institute, Boston University
- Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
- University of Michigan at Ann Arbor, MD
- Stony Brook University, BS
- Published on 5/16/2020
Kam S, Collard M, Lam J, Alani RM. Gut Microbiome Perturbations in Patients with Hidradenitis Suppurativa: A Case Series. J Invest Dermatol. 2021 01; 141(1):225-228.e2. PMID: 32422215.
- Published on 10/17/2019
Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, Wu M, Nocco S, Bonal DM, Nguyen QD, Suva ML, Bernstein BE, Alani R, Golub TR, Cole PA, Filbin MG, Shi Y. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell. 2019 11 11; 36(5):528-544.e10. PMID: 31631026.
- Published on 3/25/2019
Kim E, Zucconi BE, Wu M, Nocco SE, Meyers DJ, McGee JS, Venkatesh S, Cohen DL, Gonzalez EC, Ryu B, Cole PA, Alani RM. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma. Cancer Res. 2019 05 15; 79(10):2649-2661. PMID: 30910803.
- Published on 4/1/2018
Eisenstein A, Gonzalez EC, Raghunathan R, Xu X, Wu M, McLean EO, McGee J, Ryu B, Alani RM. Emerging Biomarkers in Cutaneous Melanoma. Mol Diagn Ther. 2018 04; 22(2):203-218. PMID: 29411301.
- Published on 2/1/2018
Eisenstein A, Panova IP, Chung HJ, Goldberg LJ, Zhang Q, Lazova R, Bhawan J, Busam KJ, Symanowski JT, Alani RM, Ryu B. Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions. Melanoma Res. 2018 Feb; 28(1):71-75. PMID: 29227334.
- Published on 1/4/2018
Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 01 04; 9(1):53. PMID: 29302039.
- Published on 3/1/2017
Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag. 2017 Mar; 4(1):13-37. PMID: 28758010.
- Published on 2/6/2017
Hsu MY, Yang MH, Schnegg CI, Hwang S, Ryu B, Alani RM. Notch3 signaling-mediated melanoma-endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis. Lab Invest. 2017 Jun; 97(6):725-736. PMID: 28165469.
- Published on 8/1/2016
Moriarty WF, Kim E, Gerber SA, Hammers H, Alani RM. Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Res. 2016 Aug; 26(4):321-8. PMID: 26881875.
- Published on 8/1/2016
Alani RM, Larson A, Falanga V. Paving a New Path Towards Academic Medicine-A Novel Approach to Graduate Medical Education in the United States. Acad Med. 2016 08; 91(8):1039-40. PMID: 27465087.
View 82 more publications: View full profile at BUMC